Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Inclusion Criteria:

- Males and females age 18 years or older at time of locally advanced or metastatic
diagnosis

- Patients with a confirmed diagnosis of locally advanced or metastatic
Gastroenteropancreatic neuroendocrine tumour (GEP-NET)

- Patients who switched treatment from long acting octreotide LAR to lanreotide, where
both treatments were received for the treatment of locally advanced or metastatic
GEP-NET. i. Treatment with long acting octreotide LAR monotherapy for at least 90-days
before treatment with lanreotide monotherapy (rescue SSA# use permitted). ii.
Treatment with lanreotide monotherapy for at least 90-days after treatment with long
acting octreotide monotherapy (rescue SSA# use permitted)

Exclusion Criteria:

- Patients with other malignant disease

- Patients who participated in a concomitant clinical trial related to treatment of
GEP-NET

- Patients being treated with a Somatostatin analogue (SSA) in combination with other
NET treatments excluding rescue SSA#

- Patients who received other primary treatment (e.g., targeted therapy, chemotherapy)
for GEP-NET during the interval between octreotide and lanreotide

- Patients with NET familial genetic syndrome (i.e., MEN1)